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ABSTRACT
Resistant starch (RS) is fermentable dietary fiber. It has been shown that inclusion
of resistant starch in the diet causes decreased body fat accumulation and altered gut
hormone profile. Gut hormone has complex effect on neuropeptides’ expression in the
brain hypothalamic area which is regarded as key factors in regulation of energy
homeostasis. In this project, thereby, it is proposed that 1) the hypothalamic
neuropeptide Y (NPY), agouti-related peptide (AgRP) and pro-opiomelanocortin (POMC)
mRNA expression may be altered by RS feeding; 2) afferent vagal nerves might be
involved in this process.
Animal experiment was conducted to investigate the hypothesis. The rats were
injected intraperitoneally with capsaicin to destroy unmyelinated small vagal afferent
nerve fibers. The cholecystokinin food suppression test was performed to validate the
effectiveness of the capsaicin treatment. Then, capsaicin treated rats and vehicle treated
rats were subdivided into a control diet or a resistant starch diet group, and fed the
corresponding diet for 65 days. At the end of study, body fat, food intake, plasma peptide
YY (PYY) and glucagon-like peptide -1 (GLP-1), and hypothalamic proopiomelanocortin, neuropeptide Y, agouti-related peptide gene expressions were
measured.
Resistant starch fed rats had decreased body fat, increased POMC expression in
the hypothalamic arcuate nucleus, and elevated plasma PYY and GLP-1 in both the
capsaicin and vehicle treated rats. Hypothalamic NPY, AgRP gene expressions and food
intake were not changed by resistant starch or capsaicin. Therefore, destruction of the
capsaicin sensitive afferent nerves did not alter the response to resistant starch in rats.
The conclusion is that dietary resistant starch might reduce body fat through increasing
vi

the hypothalamic POMC expression and vagal afferent nerves are not involved in this
process.
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CHAPTER 1
INTRODUCTION
The worldwide prevalence of obesity has risen dramatically during the past two
decades, especially in the United States. The 1998-2002 National Health and Nutrition
Examination Survey (NHANES) showed 65.1% of the U.S. adults aged at least 20 years
are over the normal weight, among which 29.8% were overweight, 30.4% were obese and
4.9% were extremely obese (NHANES 2002). Obesity, as a chronic disease per se, has a
profound impact on human health and lifespan. It leads to the increased morbidity,
decreased life quality and shortened life span. Obesity is also a risk factor for many other
diseases. Current evidence show that excess weight gain may be responsible for 65-75%
of the risk for essential hypertension and cardiovascular disorders (Hall et al.2003)
Moreover, obesity is considered as one of the main causes of type 2 diabetes (Mokdad et
al. 2003). Obesity and its related diseases are costly; in 2003, the cost of obesity related
diseases reached $75 billion in USA and continued going up (CDC, 2004). Therefore, it
is important and urgent to find effective ways to treat obesity.
Resistant starches are non-digestible fermentable dietary fibers that resist
digestion in the small intestine, but are fermented in the large intestine. It has been shown
that adding resistant starch to diets produces several health benefits, including lower body
fat storage (Brown, 2004; Higgins, 2004). However, the current understanding of the
mechanism of decreased body fat by resistant starch is incomplete. In addition to the
conventional effects as dietary fiber, such as diluting the energy density of the diet and
causing discomfort in the gut, resistant starch fed animals were also found having
significantly higher levels of peptide YY (PYY) and glucagon-like peptide -1 (GLP-1)
( Keenan, et al. 2006; Zhou et al. 2006). PYY and GLP-1 are gut satiety hormones and
1

candidates for anti-obesity drugs (Murphy et al. 2006;Young 2006). These two hormones
reduce food intake and body weight by sending signals from the gut to the brain, and
changing hypothalamic neuropeptide expression ( Wren et al. 2007).
There are two different sets of neurons: neuropeptide Y/agouti-related peptide
(NPY/AgRP) and pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the
hypothalamus. These are the key factors in modulating energy homeostasis. Activation of
POMC neurons increases energy expenditure, and activation of NPY/AgRP neurons
increases food intake (Schwartz et al. 2004; Cone et al. 2001). Studies show PYY and
GLP-1 affect the activities of hypothalamic NPY/AgRP and POMC neurons (Riediger et
al. 2004; Acuna-Goycolea et al. 2005; Larsen et al.1997; Ghamari-Langroudi et al. 2005).
Peripheral injection of PYY decreases NPY mRNA (Batterham et al. 2002; Challis et al.
2003) and increases POMC mRNA in the hypothalamus (Challis et al. 2003). The
modulation of NPY/AgRP and POMC neurons by PYY or GLP-1 can be directly or
through vagal nerves (Abbott et al.2005; Koda et al. 2005; Osaka et al.2005). The
modulation of brain neuropeptides, NPY, AgRP and POMC, by resistant starch is
unknown, except the most recent report showing that resistant starch fed mice have high
activity in hypothalamus measured by neuronal magnetic resonance imaging (MRI) ( So
et al. 2007).
This study investigates the role of hypothalamic neuropeptides and vagal nerves
on decreasing body fat by resistant starch. The hypothesis for this work is that 1) the
hypothalamic NPY/AgRP and POMC mRNA expression are altered in resistant starch
fed rats; and 2) afferent vagal nerves are involved in this process. To test the hypothesis,
rats’ visceral afferent nerves were destroyed with a neurotoxin, capsaicin to examine
whether the effect of resistant starch would be abolished. NPY, AgRP, and POMC
2

mRNA expressions in arcuate nucleus of hypothalamus were measured in rats fed
resistant starch and control diets.
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CHAPTER 2
REVIEW OF LITERATURE
Resistant Starch
The term resistant starch (RS), first coined in 1982 (Ritter et al. 1989), refers to a
sum of starch that resists digestion by amylase in the small intestine and mainly reaches
the large intestine where the undigested starch is fermented by the microflora to produce
short chain fatty acids. RS is divided into four subcategories: RS1, RS2, RS3, and RS4.
RS1 represents starch in whole grains that are in a physically inaccessible form. RS2 is a
type of starch, such as ungelatinized starch, which is tightly packed in a radial pattern and
resists digestion. The high amylose cornstarch used in the current study is an example of
a RS2. RS3 is the type of starch that is most resistant to digestion. The starch fitting in
this category is mainly retrograded amylose formed in the process of cooling the
gelatinized starch and can escape the digestion of pancreatic amylase almost totally. RS4
includes structurally modified starch by chemical treatment linking amylose strands. In
our study, the starch used is composed of 60% amylose and 56%RS.
Adding resistant starch to diets produces several health benefits, including lower
body fat storage ( Brown, 2004; Higgins, 2004). Some human studies claim that diets
containing resistant starch increase satiety and decrease food intake (Achour et al. 1997;
Liljeberg et al. 1999; Raben et al. 1994) and the opposite result has also been reported
( de Roos et al.1995). These equivocal results are due to the lack of direct comparisons
in these studies, as dietary texture and energy content used in those studies are different.
In contrast to human studies, our previous works show that body fat is consistently lower
in resistant starch fed animals compared to control animals fed the same dietary texture
and energy density diet (Garcia et al. 2003; Hegsted et al. 2003; Keenan et al.2006). Thus,
4

resistant starch might be an alternative dietary carbohydrate for developing weight
control diets.
The mechanism of decreased body fat by resistant starch is not completely
understood. As a part of the diet, RS potentially has three major effects (Keenan et
al.2006): metabolizable energy dilution, a bulking effect and fermentation to produce
short-chain fatty acids and increase PYY and GLP-1 through nutrient-gene interactions.
Resistant starch dilutes the energy density of the diet, which previously was considered
the main mechanism for decreased body fat by resistant starch. However, in our previous
studies, we balanced the energy density in the two diets, RS and EC, to exclude the
effects of energy dilution, and still obtained the similar outcome. Another assumption is
that fermentation of resistant starch causes discomfort in the gut, which leads to
decreased food intake and body weight. Nevertheless, resistant starch fed animals eat the
same or more food than controls ( Keenan et al.2006), which indicates at most only minor
effects of gut discomfort in decreased body fat. Thus, the bulking effect of fiber, which
induces the decrease of food intake on account of the distension of the GI tract, might be
considered not as a major factor on RS reducing body fat.
It is reported that resistant starch fed animals have significantly higher levels of
peptide YY (PYY) and glucagon-like peptide -1 (GLP-1) ( Keenan, et al. 2006; Zhou et
al. 2006). PYY and GLP-1 are gut secreted hormones and candidates for anti-obesity
drugs ( Murphy et al. 2006;Young 2006). Administration of GLP-1 or PYY reduces food
intake and body weight in animals and humans ( Batterham et al. 2002; Drucker et al.
2006; Neary et al. 2005). These two hormones alter energy balance by sending signals
from the gut to the brain, and result in brain neuropeptide expression changes ( Wren et al.
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2007). Therefore, the mechanism of decreased body fat by resistant starch might also
relate to the similar gut-brain connection and the regulation of brain neuropeptides.
Glucagon-like Peptide-1 (GLP-1)
GLP-1 is a satiety peptide yielded from the preproglucagon gene product in the L
cell of the distal intestine (Badman and Fliter. 2005)
GLP-1 has several forms in the circulation. The inactive forms, GLP-11-36 and
GLP-11-37 , are cleaved from preproglucagon , depending on whether the C-terminal
glycine is present. Further N-terminal truncation is required to produce the biologically
active forms, GLP-17-36 and GLP-17-37 (Mojsov et al. 1986).
GLP-1 is released into the circulation in a biphasic manner in proportion to the
calories ingested (Orskov et al. 1994). The early phase release seems to be mediated by a
neuroendocrine reflex, whereas the latter is a result of the presence of nutrients directly
with L-cells.
The action of GLP-1, as a potent incretin, including mediating glucose-dependent
insulinotropic effects (Holst et al. 1987), inhibiting gastric acid secretion and delaying
gastric emptying, as well as promoting an increase in pancreatic β-cell mass (Tolessa et al.
1998; Naslund et al. 1999). Like other gut peptides, GLP-1 also functions within the
central nervous system (CNS) as a neurotransmitter. It has been confirmed that GLP-1
receptors are distributed in a number of areas of the brain. These include the Arcuate
nucleus (ARC), the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) of
the hypothalamus and the area postrema of the brainstem (Wei et al.1995; Shughrue et al.
1996), most of which are important in appetite control. A high density of GLP-1
receptors is localized in the ARC.
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Both CNS-injected and peripherally administered GLP-1 inhibit food intake in
rodents. Turton et al. ICV administered GLP-1 to rats and demonstrated a significant
inhibition of food intake. The feeding effect was inhibited by the presence of exendin9-39,
a competitive antagonist to GLP-1(Turton et al. 1996).
Similar data were obtained from human studies. GLP-1 decreases appetite and
caloric intake in lean and obese humans in a dose-dependent manner (Gutzwiller et al.
1999a). Exendin-4, a potent agonist at GLP-1 receptors, also reduced food intake in
healthy volunteers (Edwards et al. 2001). In a recent meta-analysis of seven studies, a
significant dose-dependent decrease in appetite and caloric intake by GLP-1 infusion was
shown both in lean and obese subjects (Verdich et al. 2001).
Peptide YY (PYY)
PYY is secreted by L-cells located in the gastrointestinal tract, especially in ileum,
colon and rectum. There are two main forms of PYY in the circulation: PYY1–36;
PYY3–36 (Batterham et al. 2002). The truncated form, PYY3-36, is created by cleavage
of the N-terminal residues by dipeptidyl peptidase IV (DPP-IV (Grandt et al. 1994).
Peripheral administration of PYY has several actions, including delaying gastric
emptying and gastric secretion, and increasing ileum absorption. It has also been reported
that peripheral administration of PYY3–36 or injection directly into the ARC inhibit food
intake and reduce weight gain in rodents (Batterham et al. 2002). However, when
injected into the cerebroventricular system, PYY3-36 increases the food intake (Kanatani
et al. 2000). But in Y1 and Y5 knockout mice, this effect is weakened. PYY3-36 exhibits
relative specificity for the Y2 receptor. When it crosses the blood brain barrier, it
probably exerts its actions via the presynaptic Y2 receptor of NPY neurons in the ARC,
reducing NPY expression and consequently inhibiting feeding (Challis et al. 2003). It is
7

consistence with the discovery that the inhibitory Y2 autoreceptor is highly expressed on
NPY neurons in the ARC (Broberger et al. 1997), whereas Y1 and Y5 receptors are
localized in areas such as the PVN. Therefore, it also has been suggested that the
orexigenic effects of ICV-administered PYY and PYY3-36 are mediated through Y1 and
Y5 receptors. The ARC, with a relative lack of blood–brain barrier, is more exposed to
circulating PYY3-36 than other areas of the hypothalamus. It has been suggested that the
melanocortin system may not be essential for the mediation of the inhibitory effects of
PYY3-36 on energy intake (Challis et al. 2004).
An alternative mechanism through which the anorectic effects of PYY3-36 are
mediated has been proposed. Y2 receptor mRNA is also found expressed in the NTS and
the nodose ganglion of the vagus nerve (Koda et al.2005). Therefore, it suggests that
PYY3-36 may inhibit feeding via the vagus. Abbott et al performed bilateral
subdiaphragmatic vagotomy and transectioning of the brainstem–hypothalamic neuronal
pathways. The anorectic effects of peripheral PYY3-36 was abolished in rats underwent
either of these two procedures as well as c-fos in the ARC in response to PYY3-36
(Abbott et al. 2005).
It has been reported that PYY3-36 can affect POMC neuron activity (Challis et al.
2003). Two studies suggested that PYY 3-36 can stimulate POMC neuron activity
( Batterham et al. 2002; Challis et al. 2003). However, it still remains controversial for
the effect of PYY3-36 on POMC neuron activity: other groups have shown that PYY3-36
inhibits rather than activates hypothalamic POMC neurons ( Acuna-Goycolea et al. 2005;
Ghamari-Langroudi et al. 2005). Moreover, peripheral PYY injection still induces a
normal anorectic response in POMC knockout mice (Challis et al. 2004). Therefore, it
still remains unclear on this issue.
8

Neuropeptides in Hypothalamic Arcuate Nucleus
Arcuate nucleus, locating around the third ventricle and above the median
eminence, is the chief hypothalamic area involved in the control of food intake. Therefore,
it is also considered as the ‘master hypothalamic centre’ for feeding control. Its location
where the blood brain barrier is relatively deficient allows the entry of various peptides
from circulation, like PYY and leptin, and modifying the activity of two populations of
neuron within the ARC (Woods et al. 2003).
There are two distinct but interconnected groups of neurons in the ARC. One set
of neurons distributing in the ventromedial part of the ARC release orexigenic
neuropeptide Y and agouti-related peptide( Broberger et al. 1998). The other population
of neurons which situate in the ventrolateral part of ARC expresses anorexigenic products
of pro-opiomelanocortin and cocaine- and amphetamine-regulated transcript (Elias et al.
1998).
These neurons expressing NPY and AgRP mostly project to the paraventricular
nucleus. (Hahn et al. 1998), whereas the other set of neurons projects more broadly
within the central nervous system (CNS) to hypothalamic nuclei such as the dorsomedial
hypothalamic nucleus, the lateral hypothalamic area (LHA) and the PVN. Thus,
AgRP/NPY and CART/POMC neurons act as the primary hypothalamic site of action of
peripheral hormones. Hypothalamic nuclei, such as the PVN and the LHA, which the
ARC neurons project to, act as the second order neurons.
Neuropeptide Y (NPY)
NPY is a thirty-six-amino acid peptide and is the most powerful central enhancer
of appetite. It is widely distributed in the CNS with a predominant expression in ARC
(Håkansson-Ovesjö et al. 2000). 90% of NPY neurons co-express AgRP (Peyron et
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al.2000). NPY mRNA levels and NPY release in the ARC are enhanced in the conditions
such as low leptin levels, negative energy balance, and hypoglycemia (Swart et al. 2002).
Central administration of NPY alters the energy balance through reducing energy
expenditure, inducing striking hyperphagia and promoting adipogenesis in rats (Pinto et
al. 2004).
Although NPY is a potent orexigenic neuronpeptide, NPY-knock-out mice show
normal body weight and adiposity (Erickson et al. 1996). That is probably due to a
compensatory and redundant mechanism in the orexigenic pathways. This is supported by
the observation that adult mice underwent selective ablation of AgRP/NPY neurons
became hypophagia and leanness (Gropp et al. 2005; Luquet et al. 2005).
NPY receptors are G-protein-coupled receptors. To date, six have been isolated,
named Y1–Y6. (Kalra et al.1999). Most of these receptors are present in rat brain, except
Y6, which is absent in rats and only found active in mice (Inui, 1999). Y1 and Y5 seem
to be involved in mediating the NPY orexigenic effects (Stanley et al., 2005). Now their
antagonists are under investigation as antiobesity agents.
Melanocortins
Melanocortin system is critical for the regulation of energy homeostasis: the
defects in MC4 are responsible for up to 6% of monogenetic obesity in humans
(MacKenzie, 2006). The melanocortin system includes neurons expressing proopiomelanocortin (POMC) in arcuate nucleus and nucleus of the solitary tract (NTS),
NPY/AGRP neurons originating in ARC and downstream targets of these neurons
expressing melanocortin receptor3 and 4 (Cone, 2005).
Among the products of cleavage of POMC is α-melanocyte-stimulating hormone,
a peptide which can bind melanocortin receptor 4 (MC4) and promote energy expenditure
10

(Cone, 2006). Thereby Pro-opiomelanocortin (POMC) neurons are suggested to be
primarily anorexigenic neurons. On the contrary to the POMC derived peptides, AgRP is
an endogenous melanocortin receptor antagonist which leads to energy excess (Bagnol,
1999). Overexpression of AgRP blocks MC4 and results in obesity. AgRP is exclusively
co-expressed in the NPY-containing neurons of the arcuate nucleus.
MC3R mRNA was found coexpressed in both AGRP and POMC neurons in the
ARC; however, neither AGRP nor POMC cells displayed MC4R mRNA (Bagnol et
al.,1999). Expression of the MC3R by POMC neurons provides a potential circuit for
amplification of AGRP-mediated signals, whereas the expression of the MC3R by AGRP
neurons provides a potential circuit for negative autoregulation of POMC-mediated
signals. Together with other evidence such as, MC3R specific agonist inhibiting
spontaneous firing of POMC neurons(Cowley et al., 2001) and increasing food intake by
peripheral administration of a MC3-R selected agonist (Marks et al., 2006), MC3-R is
now regarded as an inhibitory auto-receptor on the ARC melanocortin circuit.
MC4R shows intense distribution in the hypothalamic nuclei including the PVN,
the DMH and the LHA (Liu et al., 2003). MC4R-overexpression in the PVN and
amygdala, hyperphagia is completely reversed, whereas reduced energy expenditure is
unaffected, suggesting that MC4R in the PVN specifically regulates food intake, while
MC4R in other regions mainly controls energy expenditure (Balthasar et al. 2005).
Overall, the current view on hypothalamic control of energy homeostasis is that it
is regulated via the balance between orexigenic NPY/AGRP neurons and anorexigenic
POMC neurons.
Capsaicin
Capsaicin is the active ingredient in hot chilli peppers. It is present in large
11

quantities in the white pith tissue which holds the seeds. However, the seeds do not
contain any capsaicin.
Capsaicin binds to a receptor called the vanilloid receptor subtype 1 (VR1), an ion
channel-type receptor (winter et al., 1995). When this receptor is activated, it increases
membrane permeability to cations, like calcium and sodium, allowing them to pass
through the cell membrane and into the cell from outside. The capsaicin caused
"depolarization" of the neuron stimulates it to signal the brain and produces a burning and
painful feeling similar as that excessive heat would (Dray, 1992). But for prolonged
periods of application, capsaicin would cause irreversible toxic effects resulting in the
loss of sensory neurons. Although the mechanisms are unclear, it has been shown that the
increase in calcium concentration may activate some calcium-dependent proteases and
leads to cell death (Chard et al., 1995).
Capsaicin binds to and activates the thinly myelinated A primary sensory neurons
and unmyelinated C-fibers. Intraperitoneal capsiacin destroys vagal (also some non-vagal,
like trigeminal) sensory fibers (winter et al., 1995). Systemic injection with large dose of
capsaicin can degenerate targeted C-fiber terminals as well as those beyond the area of
interest. It also brings some adverse effects, for example, the pulmonary chemoreflex
and reflex bronchoconstriction caused by the activation of the pulmonary C fibre VR1
(Nault et al., 1999) and cardiac dysfunction (Zvara et al., 2006). Perivagal application of
capsaicin needs very small dose of capsaicin and isn’t accompanied with systemic
adverse effect (Cakir et al., 2007). However, it was observed that, with localized
application of capsaicin, c-fiber degenerated distally and extensive axonal sprouting
could be seen from the proximal nerve (winter et al., 1995).
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CHAPTER 3
DIETARY RESISTANT STARCH INCREASES HYPOTHALAMIC POMC
EXPRESSION INDEPENDENT OF CAPSAICIN-SENSITIVE NEURONS IN
RATS
Introduction
Resistant starches (RS) are non-digestible, fermentable fibers that have potential
to treat obesity and related disease. Our previous research showed that RS reduced body
fat in rodents (Keenan et al. 2006). Also, we found RS feeding increased the gene
expression and plasma concentration of peptide YY (PYY) and glucagon-like peptide -1
(GLP-1) (Zhou et al. 2006). PYY and GLP-1 are two satiety hormones that are released
from the gut and signal the brain to alter the energy balance by affecting activities of two
sets of neurons in the hypothalamus, NPY/AGRP and POMC. Although the essential role
of NPY/AGRP and POMC in energy homeostasis is well established, it is not clear that
how PYY and GLP-1 affect NPY/AGRP and POMC neurons. Some studies have shown
that the effect of these two hormones could be attenuated by ablation of the vagal trunk
(Abbott et al. 2005; Koda et al. 2005), while another study did not observe this effect
(Osaka et al. 2005). Because RS fed animals had reduced body fat and increased
expression of PYY and GLP-1 (Zhou et al. 2006), we hypothesize that 1) the
hypothalamic NPY/AGRP and POMC mRNA expression may be altered by RS feeding;
2) afferent vagal nerves are involved in this process. In this study, therefore, we measured
the impact of RS feeding on mRNA expression of three neuropeptides in the arcuate
nucleus of the hypothalamus to investigate the mechanism of RS on reducing body fat.
Additionally, we destroyed visceral afferent nerves with a neurotoxin, capsaicin, to
examine whether the effect of RS would be abolished.
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Methods and Materials
Animals and Diet
Fifty-two male Sprague-Dawley rats aged 7~8 weeks and weighing 150~200g at
the beginning of the study, were obtained from Harlan Industries (Indianapolis, IN). They
were housed individually in hanging wire-mesh cages in a temperature-controlled room
(22±1 oC) on a 12 h/12 h light/dark cycle with the light on at 7am. Rats were acclimated
for 1 week to a powdered diet and to the cages. Water and assigned diet were available ad
libitum during the experiment except as noted. The protocols were approved by
Pennington Biomedical Research Institutional Animal Care and Use Committee.
The composition of the two experimental diets used in this study is listed in Table
1. The resistant starch (RS) diet contained 30% (weight/weight) resistant starch (HiMaize® cornstarch; National Starch & Chemical Co., Bridgewater, NJ). The equal
energy density control (EC) diet had 100% amylopectin cornstarch (Amioca®; National
Starch and Chemical Co.) as the carbohydrate source and equal energy density as RS diet
(3.3kcal/g) by using non-fermentable cellulose (Dyets, Bethlehem, PA) to dilute the
energy density.
Capsaicin Treatment
After one week of acclimation, rats were grouped according to weight with a
randomized block design. Two groups of rats were injected intraperitoneally with either
capsaicin or vehicle under inhalation anesthesia (isoflurane). The total capsaicin dose
(117.5mg/kg; Sigma Chemical) was administered as a series of injections on three
consecutive days in increasing doses (12.5, 30, and 75mg/kg) ( Kelly et al. 2000).
Capsaicin was dissolved in a mixed solution of 10% ethanol, 10% Tween 80 and 80%

14

Table 1. Experimental Diet Composition

Ingredients

Control

100% amylopectin

grams

kcal

424.5

1485.8

RS
grams

0

kcal

0

High amylose starch
60% amylose/

0

0

530.7

1486

40%amylopectin
Sucrose

100

400

100

400

Casein

200

716

200

716

Soybean oil

70

591.5

70

591.5

156.2

0

50

0

Mineral mix

35

30.8

35

30.8

Vitamin mix

10

38.7

10

38.7

Choline chloride

1.3

0

1.3

0

L-cystine

3.0

12

3.0

12

Cellulose

1000 g/kg

3.3kcal/g

1000 g/kg

15

3.3kcal /g

sterile saline. During the injection of capsaicin, artificial ventilation and chest massage
were provided to all rats who exhibited respiratory arrest, which typically occurred in the
first few minutes after the injection. The survival rate during the capsaicin treatment was
70%.
The effectiveness of the capsaicin treatment was validated using the
cholecystokinin (CCK) feeding-suppression test, a capsaicin-sensitive vagal nerve
dependent response ( Kelly et al. 2000).
CCK Feeding- Suppression Test
Four days after the last capsaicin or vehicle injection, all rats were injected
intraperitoneally with either CCK or saline after an overnight fasting. Half of the
capsaicin and vehicle treated rats received CCK (6ug/kg), and the other half received the
same volume of saline five minutes prior to given access to food. Then food intake was
measured for the following 30 minutes. Three days later, the same test was repeated
except that the rats receiving CCK previously were injected with saline, and the rats that
received saline previously were injected with CCK. In the vehicle-treated rats, the
administration of CCK significantly suppressed 30 minute food intakes in overnight
fasted rats (5.22±0.14 vs. 2.86±0.17; p<0.001). But all capsaicin treated rats failed to
respond to CCK and did not reduce food intake (4.63±0.19 vs. 4.18±0.15; p=0.12).
Experimental Design
Nine days after the capsaicin treatment, both capsaicin and vehicle-treated rats
were divided into two diet treatment groups, resistant starch and energy control, by
randomized block design based on their weight. The four groups of rats were fed their
assigned diets for 65 days. Food intake and body weight were measured three times per
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week throughout the experiment. After 65 days, the animals were sacrificed via
decapitation. Different fat pads (epididymal fat, perirenal fat, and remaining fat in the
abdominal area, defined as abdominal fat) were removed and weighed. Total body fat
used for body fat calculation was the sum of epididymal fat, perirenal fat, and abdominal
fat. The gastrointestinal (GI) tract was removed and weighed after removal of mesenteric
fat. Disemboweled weight was calculated by subtracting GI weight from body weight.
Plasma Assays
Blood was collected in EDTA tubes with final EDTA concentration 1.8mg/ml
blood and centrifuged at 4000 X g for 20 minutes to extract plasma. Plasma PYY and
GLP-1 were measured by radioimmunoassay with RIA kits from Linco Research Inc. (St.
Louis, MO).
To make the standard curve for PYY, 100 ul of the six standards (15.6-500pg/ml)
was mixed with 100ul PYY antibody, and 300ul assay buffer in tubes to incubate
overnight at 4 oC. On the second day, 100 ul 125I-Rat PYY was added into the mixture
and incubated overnight at 4 oC. On day three, 10 ul Rabbit Carrier and 1.0 cold
precipitating Reagent were pipetted into the tubes in turn. After following incubation and
centrifugation, supernatant was decanted from the tubes and radiation counts were
determined with gamma counter. The counts were regressed on the PYY standard
concentration to obtain the standard curve. For the sample measurement, the same
procedure was performed. The PYY concentration in each sample was calculated using
the standard curve, expressed in pg/m.
To make the standard curve for GLP-1, 100 ul of the seven standards (10-1000pM)
was mixed with 100ul GLP-1 antibody and 400ul assay buffer in tubes to incubate
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overnight at 4 oC. On the second day, 100 ul 125I-Rat GLP-1 was added into the mixture
and incubated overnight at 4 oC. On day three, 10 ul Rabbit Carrier and 1.0 cold
precipitating Reagent were pipetted into the tubes in turn. After following incubation and
centrifugation, supernatant was decanted from the tubes and radiation counts were
determined with gamma counter. The counts were regressed on the GLP-1 standard
concentration to obtain the standard curve. For the sample measurement, the same
procedure was performed. The GLP-1 concentration in each sample was calculated using
the standard curve, expressed in pM.
Microdissection of Arcuate Nucleus (ARC) in Hypothalamus
Brains from decapitated rats were quickly removed, frozen on dry ice and stored
at -70 oC. The middle brain was dissected using a cryostat. Microdissection of the ARC
was performed using the procedure described by Palkovits ( Palkovits, 1988). Five
continuous coronal sections were collected starting from Bregman -2.12mm to -3.4mm
for the ARC micropunch. The thicknesses of sections were 300um each. The micropunch
was performed bilaterally under a microscope, using a needle (Stoelting, Chicago, IL)
with an inner diameter of 0.51mm. Immediately after each punch, the tissue was put into
100 ul of ice-cold 2- mecaptoethanol-lysis buffer (ratio is 0.7:100), and vortex until the
sample was homogenized. Then equal volumes of cold 70% ethanol were added to the
lysate and mixed thoroughly for 10seconds. The mixture was then stored at -70 oC until
we began to perform the RNA extraction.
Measurements of NPY, AGRP and POMC mRNA Expression
RNA was extracted from micro-punched tissue using Absolutely RNA microprep
kit from Stratagene (La Jolla, CA). The ethanol-lysate mixtures from one rat was

18

vortexed again for 5 sec, transferred to a RNA-binding cup that was sat on a 2-ml
collection tube, and centrifuged for 1 min at 18,000 x g at 4 oC. All the following spin
o
condition is 18,000 x g at 4 C. The filtrate was discarded and 600 ul of low-salt wash

buffer was added to the cup, followed by 1 min centrifuge. After discarding the filtrate,
and spinning the cup for another 2 min to dry the fiber matrix, 30 ul of RNase-free DNase
I solution was pipetted directly onto the fiber matrix. Then the cup was incubated in a 37
o

C water bath for 15 min. The RNA was washed with 500 ul of high-salt, 600 ul and 300

ul of low-salt wash buffer respectively; one-minute spin was applied after each wash.
Following the final wash the cup was spun for 2 min to dry the fiber matrix. Then the cup
was moved to a 1.5-ml collection tube, and 20 ul of elution buffer was added directly
onto the fiber matrix. After a 2-min incubation at room temperature, the cup was spun for
1 min. For RNA quantification, 1.5 ul of sample RNA was used to detect the optical
density (OD) 260 and OD280 using a nanodrop.
The gene transcription for AgRP, NPY, and POMC in the ARC of the
hypothalamus was determined using real-time reverse transcriptase polymerase chain
reaction, and results were expressed as a ratio to the expression of the constitutive gene
cyclophilin. The sequences of the primers and probes for rat cyclophilin, NPY and AGRP
were listed in Table 2. The probe and primers for POMC (assay identification no.
Rn00595020_ml) were purchased from Applied Biosystems(Foster City, CA).Real time
RT-PCR reaction mixture was 10 ul of total volume, including 9ng of sample RNA, 1 ul
of 10 X Tagman buffer, 5.5mM MgCl2, dATP, dCTP, dUTP and dGTP each 0.3 mM,
500 nM forward primers, 500 nM reverse primers, 200 nMTaqman probes, 7.5 U RNase
inhibitor, 5 U MuLV reverse transcriptase, 0.3 U AmpliTaq Gold DNA polymerase and
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Table 2. The sequences of primers and probes for real time RT-PCR. F: forward primer,
R: reverse primer, P: Taqman probe, CYC: cyclophilin, NPY, neuropeptide Y, AgRP:
agouti-related peptide.

Gene

Sequence

Genebank

Rat CYC

F: 5'CCCACCGTGTTCTTCGACAT3'
M15933
R: 5'TGCAAACAGCTCGAAGCAGA 3'
P: 5'CAAGGGCTCGCCATCAGCCG 3'
-----------------------------------------------------------------------------------------------------------Rat NPY
F: 5' TCTGCCTGTCCCACCAATG 3'
M20373
R: 5' CAACGACAACAAGGGAAATGG3'
P: 5' CCACCACCAGGCTGGATTCCGA 3'
----------------------------------------------------------------------------------------------------------Rat AGRP
F: 5' TTGGCAGAGGTGCTAGATCCA 3'
AF206017
R: 5' AGGACTCGTGCAGCCTTACAC 3'
P: 5' CGAGTCTCGTTCTCCGCGTCGC 3'
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RNase-free H2O. Each sample was tested in duplicate. The one-step real-time reverse
transcriptase polymerase chain reaction condition is 48 oC for 30 min, 95oC for 10 min for
o
o
one cycle, 95 C for 15 sec and 60 C for 1 min for 40 cycles.

Statistical Analysis
Data are presented as means ±SEM. Statistical analyses were performed using the
Statistical Analysis System (SAS 9.1). A factorial arrangement of the treatments (twoway ANOVA) was used to examine the influence of the two main effects of diet and
capsaicin/vehicle treatment on all measurements. Subgroup means were compared by
Tukey’s method.
Results
POMC, NPY, and AgRP mRNA expression in arcuate nucleus of hypothalamus
POMC expression in the ARC (Figure 1) was significantly up-regulated by
dietary resistant starch (p<0.05). Capsaicin treatment did not affect the influence of
resistant starch on POMC expression (p>0.05). There were no effects of dietary resistant
starch or capsaicin injection on expression of NPY and AgRP (Figure 1).
Fat Pads Weights
Compared with rats fed the control diet, dietary resistant starch significantly
decreased total body fat and fat/disemboweled weight in both the vehicle and capsaicin
groups. There was no interaction between diet and treatment (p> 0.05), although both diet
and treatment had an effect on these two measures (diet p<0.001, treatment p<0.01)
(Figures 2).
Plasma PYY and GLP-1 Concentrations
Capsaicin treatment did not affect the increase of plasma PYY and GLP-1
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Figure 1. Dietary resistant starch increases POMC (a), but not NPY (b) and AgRP (c)
mRNA expressions in arcuate nucleus of resistant starch fed rats treated with vehicle or
capsaicin. Data are mean ± SEM for group of 7-9 rats. For POMC mRNA expression,
diet: P<0.05, capsaicin: P>0.05, Interaction: P>0.05 by two way ANOVA. For NPY and
AgRP, there were no significant effects on diet, capsaicin, and interaction. * P<0.05 vs.
controls within the same treatment (vehicle or capsaicin).
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Figure 2.Total body fat (a) and percentage of body fat/ disemboweled body weight (b)
were decreased in resistant starch fed rats treated with vehicle or capsaicin. Data are
mean ± SEM for group of 10-11 rats. Two way ANOVA analysis indicates there were
significant diet (p < 0.001) and a significant capsaicin treatment effects (p < 0.01), with
no interaction effect. * P<0.05 vs. controls within the same treatment (vehicle or
capsaicin)
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concentrations (treatment p>0.05, diet p<0.001) induced by RS feeding. (Figures 3)
Food intake and disemboweled weight
There were no statistical differences of food intake between control and RS
fed rats. It demonstrated no or minimal discomfort with the consumption of resistant
starch at the levels in their diet. Because RS fed rats had significantly heavier GI contents,
the disemboweled body weight was used to exclude GI contents from body weight.
There was no significant difference for disemboweled body weight between control and
RS fed rats within capsaicin or vehicle treatment groups. (Table 3)
Discussion
In this study, we investigate the mechanism of decreased body fat by dietary
resistant starch. We demonstrate that dietary resistant starch increases hypothalamic
POMC expression independent of capsaicin-sensitive neurons in rats. Specifically, we
measured mRNA expressions of POMC, NPY and AgRP in the arcuate nucleus in the
context of resistant starch feeding and capsaicin treatment. To our knowledge, our
finding provides the first direct evidence that dietary resistant starch alters brain
neuropeptide expression in rats.
Feeding resistant starch significantly up-regulated the expression of POMC, but
had no effect on the expressions of NPY and AgRP in rats. These results are consistent
with the observation that food intake is similar between control and RS fed rats in our
study. Actually, RS fed rats have a tendency to eat more food. Although studies
showing that resistant starch fed animals decreased energy intake compared to the control
diet fed animals, we noticed that the control diet used in those studies had higher energy
density than the RS diet ( So et al. 2007). In human subjects, there are uncertain and

24

a

Total GLP-1

b

Total PYY
120

*

180

*

*

*

80

PM

P G /M L

120

40

60

0

0

vehicle

vehicle

capsaicin

Control diet

capsaicin

Resistant starch diet

Figure 3． Plasma total PYY (a) and total GLP-1 (b) concentrations were increased in
rats fed resistant starch. Data are mean ± SEM for group of 10-11 rats. For both 3(a) and
3(b), there was a significant diet effect (p < 0.001) but not a capsaicin treatment effect (p
>0.05) and no interaction effect (p >0.05). * P<0.05 vs. controls within the same
treatment (vehicle or capsaicin).
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Table 3 Food intakes and body weight in resistant starch fed rats treated with capsaicin or
vehicle.
Group

Cumulative food intake (g)

Disemboweled body weight (g)

Vehicle-C
1256.6±9.0
391.3±7.22
Vehicle –RS
1302.6±9.8
379.1±9.6
Capsaicin-C
1380.5±15.6
377.75±7.53
Capsaicin-RS
1403.9±9.8
360.3±11.7
Vehicle-C: vehicle treated rats fed control diet
Vehicle-RS: vehicle treated rats fed resistant starch diet
Capsaicin-C: capsaicin treated rats fed control diet
Capsaicin-RS: capsaicin treated rats fed resistant starch diet
There were no significant difference in food intake and disemboweled body weight
between control and RS fed rats. However, rats treated with capsaicin had lower
disemboweled body weights compare to vehicle-treated rats. Data are mean ± SEM for
group of 10-11 rats
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contradictive reports on the satiety effects of RS ( Higgins et al. 2004), but fatty acid
oxidation is significantly increased after consumption of resistant starch ( Higgins et al.
2004).
Thus, the decreased body fat in RS fed rats is most likely the result of increased
energy expenditure and activation of POMC neurons, rather than from decreased food
intake via altering NPY/AgRP neurons.
The increased POMC and decreased body fat in RS fed rats are independent of
capsaicin sensitive vagal nerves because the capsaicin treatment did not block any
resistant starch effects tested in the present study. In vehicle treated rats, dietary resistant
starch decreased body fat and increased plasma PYY and GLP-1 levels, which is
consistent with our previous publications (Keenan et al. 2006; Zhou et al. 2006).
Interestingly, the effect of RS was retained in rats when their vagal nerves were destroyed
by capsaicin, implying the signals generated from the gut act directly on the brain, not via
the vagal nerve. Still, there is a small chance that non-capsaicin sensitive vagal nerves
can convey signals from the gut to the brain, because capsaicin only destroys small,
unmyelinated primary sensory vagal afferent nerves ( Ritter et al. 1989). Regardless, our
results indicate that the effects of resistant starch on body fat and hypothalamic POMC
gene expression do not rely on the involvement of capsaicin sensitive nerves.
Our results bring an interesting question: what causes the increased POMC
expression in resistant starch fed rats? Resistant starch potentially has three major effects
as a part of the diet: metabolizable energy dilution, a bulking effect, and fermentation to
produce short-chain fatty acids and increase PYY and GLP-1 (Keenan et al. 2006). In
our study, control and resistant starch diets have the same energy density, so the energy
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dilution effect can be excluded. The bulking effect is due to the high fiber content in
resistant starch diet. If the bulking causes the changes in POMC, destroying vagal
afferent nerves should prevent the changes, as distension signals from the gut to the brain
are vagal afferent nerve dependent (Phillips et al. 2000). But our results indicate
otherwise. Thus, the mechanism of increased POMC was narrowed down to the
fermentation of resistant starch and the subsequent increases of PYY and GLP-1. Further
studies are needed for a conclusive determination for the cause of increased POMC in
resistant starch fed animals.
Another question raised from our results is why RS fed rats do not decrease food
intake despite having higher PYY and GLP-1? Our previous unpublished results indicate
a broader gut-secreted hormone profile is changed by dietary resistant starch. We suspect
that the other hormones/factors modulated by resistant starch may oppose the effects of
PYY and GLP-1 on food intake. Additionally, both PYY and GLP-1 have active and
inactive forms (Wren et al. 2007; Baggio et al. 2007). Total PYY and GLP-1 were
increased in our study, while PYY and GLP-1 reduction of food intake is based on
injecting active forms of PYY and GLP-1 ( Neary et al. 2005; Batterham et al. 2003).
PYY has two forms: PYY 1-36 and PYY 3-36. When PYY1-36 is released from L-cells
of the ileum and large intestine, it is quickly converted to PYY3-36 by the enzyme
dipeptidyl peptidase-IV (DPP-IV) (Wren et al. 2007). PYY 1-36 and PYY 3-36 have
counteracting effects on food intake. PYY3-36 has been shown to inhibit appetite and
decrease food intake by binding to Y2-receptors and exerting a negative impact on the
NPY neuron (Batterham et al. 2002). In contrast, central injection of PYY 1-36 prompts
food intake through an Y1-receptor mediated action ( Ballantyne, 2006). Our
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unpublished data have showed that the consistent higher plasma total PYY was observed
over 24 hours in RS fed rats, suggesting a continuously-released pattern for PYY in RS
fed rats. This release pattern is different from meal-stimulated PYY releases. Thus, the
ratio of PYY1-36 and PYY3-36 may be high in RS fed animals and the counteracting effects
of these two peptides would account for the lack of food intake differences between RS
fed rats and controls.
PYY3-36 and GLP-1 can also directly affect POMC neuron activity ( Challis et al.
2003; Ma et al. 2007). Two studies suggested that PYY 3-36 can stimulate POMC neuron
activity (Batterham et al. 2002; Challis et al. 2003). However, it still remains
controversial for the effect of PYY3-36 on POMC neuron activity: other groups have
shown that PYY3-36 inhibits rather than activates hypothalamic POMC neurons ( AcunaGoycolea et al. 2005; Ghamari-Langroudi et al. 2005). Moreover, peripheral PYY
injection still induces a normal anorectic response in POMC knockout mice (Challis et al.
2004). Therefore, effects of resistant starch on stimulating POMC expression are more
likely explained by elevated GLP-1 in RS fed animals. This deduction is based on a
combination of our results and the following evidence. First, GLP-1 receptors are found
located in the ARC where they overlap hypothalamic POMC neurons’ residency
( Merchenthaler et al. 1999). Second, GLP-1 excites POMC neurons postsynaptically via
interaction with GLP-1 receptors in POMC cells from mouse ARC brain slices ( Ma et al.
2007). Third, our RS fed rats had decreased body fat without reduced energy intake
compared to controls. This indicates that there was increased energy expenditure in RS
fed rats, and GLP-1 increased energy expenditure (Osaka et al. 2005). Further studies are
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needed to block the GLP-1 action to determine if changes on POMC in RS fed rats could
also be blocked.
In conclusion, the mechanism of decreased body fat by resistant starch is linked to
increased neuropeptide POMC gene expression in the hypothalamus and such an effect is
independent of involvement of visceral afferent capsaicin-sensitive neurons. Our
findings provide a further understanding of how resistant starch works as a dietary
ingredient to reduce body fat.
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CHAPTER 4
CONCLUSIONS
The work in this thesis focuses on the role of hypothalamic neuropeptides and
vagal nerves on decreasing body fat by resistant starch. We measured mRNA expressions
of POMC, NPY and AgRP in the arcuate nucleus in the context of resistant starch feeding
and capsaicin treatment. We showed that Feeding resistant starch significantly upregulated the expression of POMC, but had no effect on the expressions of NPY and
AgRP in rats. We further demonstrated that the capsaicin treated rats had a similar
decreased body fat and elevated plasma PYY and GLP-1 levels as vehicle treated rats.
We provide evidence to indicate that the mechanism of decreased body fat by
resistant starch is linked to increased neuropeptide POMC gene expression in the
hypothalamus and such an effect is independent of involvement of visceral afferent
capsaicin-sensitive neurons. Further work is needed to verify whether dietary resistant
starch reduce body fat by increasing energy expenditure; the role of PYY and GLP-1 in
resistant starch’s effect; and the application to human.
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